a number of trpv4 agonists and antagonists have been identified since its discovery. the discovery of unselective modulators (e.g. antagonist ruthenium red) was followed by the apparition of more potent (agonist 4apdd) or selective (antagonist rn-1734) compounds, including some with bioavailability suitable for in vivo pharmacology studies such as agonist gsk1016790a (with ~10 fold selectivity vs trpv1), and antagonists hc-067047 (with ~5 fold selectivity vs herg and ~10 fold selectivity vs trpm8) and rn-9893 (with ~50 fold selectivity vs trpm8 and ~10 fold selectivity vs m1).